

PG3731US2

In the Claims:

1 - 21. (Canceled)

22. (Currently Amended) A method of treatment of a mammal suffering from NUD which comprises administering an effective amount of a COX-2 inhibitor or a pharmaceutically acceptable salt or solvate derivative thereof.

23. (Currently Amended) A method of treatment according to claim 22 wherein the COX-2 inhibitor is selected from the group consisting of: 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine; 8-acetyl-3-(4-fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-imidazo[1,2-a]pyridine; 4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide; N-isobutyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine; celecoxib; rofecoxib; valdecoxib; parecoxib; COX 189; etoricoxib (MK663); 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide (JTE-522); nimesulide; flosulide; 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-(2-propoxy)-5H-furanone (DFP); methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl) (NS398); and 5-methanesulfonamido-6-(2,4-difluorothiophenyl)-1-indanone (L-745337); or a pharmaceutically acceptable salt or solvate derivative thereof.

24. (Currently Amended) A method of treatment of man suffering from NUD which comprises administering an effective amount of a COX-2 inhibitor or a pharmaceutically acceptable salt or solvate derivative thereof.

25. (Currently Amended) A method of treatment according to claim 24 wherein the COX-2 inhibitor is selected from the group consisting of: 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine; 8-acetyl-3-(4-fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-imidazo[1,2-a]pyridine; 4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide; N-isobutyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine; celecoxib; rofecoxib; valdecoxib;

PG3731US2

parecoxib; COX 189; etoricoxib (MK663); 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide (JTE-522); nimesulide; flosulide; 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-(2-propoxy)-5H-furanone (DFP); methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl) (NS398); and 5-methanesulfonamido-6-(2,4-difluorothiophenyl)-1-indanone (L-745337); or a pharmaceutically acceptable salt or solvate derivative thereof.